Repertoire Immune bags $189 million financing

13 April 2021

Clinical-stage US biotech Repertoire Immune Medicines today announced the completion of a $189 million Series B financing.

Joining Flagship Pioneering, Repertoire’s institutional founder and principal backer, are new and existing investors including Softbank Vision Fund 2, the Public Sector Pension Investment Board (PSP Investments), the Alaska Permanent Fund, Invus, and others.

Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical and pre-clinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities. Founded by Flagship Pioneering, Repertoire has raised more than $350 million in the aggregate to date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK